JP2010534664A - Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物 - Google Patents

Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物 Download PDF

Info

Publication number
JP2010534664A
JP2010534664A JP2010518314A JP2010518314A JP2010534664A JP 2010534664 A JP2010534664 A JP 2010534664A JP 2010518314 A JP2010518314 A JP 2010518314A JP 2010518314 A JP2010518314 A JP 2010518314A JP 2010534664 A JP2010534664 A JP 2010534664A
Authority
JP
Japan
Prior art keywords
antibody
fibrosis
antibodies
human
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010518314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534664A5 (https=
Inventor
デユダス，ポール
サグー，サラ
エロソ，エム・マール
フアレル，フランシス
Original Assignee
セントコア・オーソ・バイオテツク・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントコア・オーソ・バイオテツク・インコーポレーテツド filed Critical セントコア・オーソ・バイオテツク・インコーポレーテツド
Publication of JP2010534664A publication Critical patent/JP2010534664A/ja
Publication of JP2010534664A5 publication Critical patent/JP2010534664A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010518314A 2007-07-23 2008-07-21 Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物 Pending JP2010534664A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95127007P 2007-07-23 2007-07-23
US95541407P 2007-08-13 2007-08-13
PCT/US2008/070588 WO2009015063A2 (en) 2007-07-23 2008-07-21 Methods and compositions for treating fibrosis related disorders using il-17 antagonists

Publications (2)

Publication Number Publication Date
JP2010534664A true JP2010534664A (ja) 2010-11-11
JP2010534664A5 JP2010534664A5 (https=) 2011-08-11

Family

ID=40282097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518314A Pending JP2010534664A (ja) 2007-07-23 2008-07-21 Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物

Country Status (5)

Country Link
US (1) US20110091378A1 (https=)
EP (1) EP2182943B1 (https=)
JP (1) JP2010534664A (https=)
ES (1) ES2614735T3 (https=)
WO (1) WO2009015063A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
TWI474833B (zh) * 2009-04-01 2015-03-01 Genentech Inc 胰島素阻抗性疾病之治療
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
JP2011032170A (ja) * 2009-07-29 2011-02-17 Morinaga Milk Ind Co Ltd ヒト細胞ｉｌ−１７産生抑制剤
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
CA2823549A1 (en) * 2011-01-04 2012-07-12 Robert Nussenblatt Methods of treating age-related macular degeneration
EP3318571B1 (en) * 2011-03-16 2021-02-17 F. Hoffmann-La Roche AG Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN109796534B (zh) * 2017-11-16 2021-08-10 北京比洋生物技术有限公司 抗il-17抗体/tnfr ecd融合蛋白及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies
WO2006088833A2 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
MXPA06014465A (es) * 2004-06-10 2007-05-16 Zymogenetics Inc Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2660463C (en) * 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies
WO2006088833A2 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor

Also Published As

Publication number Publication date
WO2009015063A8 (en) 2009-07-23
WO2009015063A3 (en) 2009-03-19
US20110091378A1 (en) 2011-04-21
EP2182943A4 (en) 2010-10-06
ES2614735T3 (es) 2017-06-01
EP2182943A2 (en) 2010-05-12
WO2009015063A2 (en) 2009-01-29
EP2182943B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
JP6564438B2 (ja) 抗−ｔｎｆ抗体、組成物、方法および使用
US7371825B2 (en) Anti-MCP-1 antibodies, compositions, methods and uses
AU2010202813B2 (en) Anti- MCP-1 antibodies, compositions, methods and uses
US8114964B2 (en) Anti-MCP-1 antibodies, compositions, methods and uses
EP2182943B1 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
KR20240038148A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
JP2008546374A5 (https=)
US20100254992A1 (en) Anti-mcp-1 antibodies, compositions, methods and uses
KR20210141976A (ko) 항-tnf 항체 조성물의 제조 방법
KR20220030952A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2007146857A2 (en) Anti- mcp-1 antibodies expressed in lemna, compositions, methods and uses
KR20230121110A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물,및 방법
KR20210118878A (ko) 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130705

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131015